OptimizeRx Corp. (NASDAQ:OPRX) Given Average Rating of “Moderate Buy” by Analysts

OptimizeRx Corp. (NASDAQ:OPRX) has been given a consensus rating of “Moderate Buy” by the nine analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $13.4286.

Several equities research analysts have issued reports on the stock. Zacks Research cut shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 4th. Weiss Ratings lowered shares of OptimizeRx from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, May 14th. Stifel Nicolaus reduced their price objective on shares of OptimizeRx from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Lake Street Capital reduced their price objective on shares of OptimizeRx from $20.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Finally, Stephens decreased their target price on shares of OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 13th.

OptimizeRx Stock Performance

NASDAQ OPRX opened at $7.08 on Friday. OptimizeRx has a fifty-two week low of $4.54 and a fifty-two week high of $22.25. The stock has a market cap of $132.82 million, a price-to-earnings ratio of 20.23 and a beta of 1.08. The business has a fifty day moving average of $5.86 and a 200-day moving average of $6.88. The company has a quick ratio of 5.37, a current ratio of 5.37 and a debt-to-equity ratio of 0.16.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.13. The business had revenue of $19.84 million for the quarter, compared to the consensus estimate of $18.74 million. OptimizeRx had a return on equity of 10.86% and a net margin of 6.37%. As a group, analysts predict that OptimizeRx will post 0.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On OptimizeRx

Several hedge funds have recently made changes to their positions in the business. Segall Bryant & Hamill LLC acquired a new position in shares of OptimizeRx during the 1st quarter valued at about $1,185,000. Next Century Growth Investors LLC boosted its position in shares of OptimizeRx by 139.8% in the fourth quarter. Next Century Growth Investors LLC now owns 505,407 shares of the company’s stock worth $6,196,000 after acquiring an additional 294,688 shares during the last quarter. Rice Hall James & Associates LLC boosted its position in shares of OptimizeRx by 1.9% in the first quarter. Rice Hall James & Associates LLC now owns 601,921 shares of the company’s stock worth $3,780,000 after acquiring an additional 11,247 shares during the last quarter. State of Wyoming grew its holdings in OptimizeRx by 234.6% in the first quarter. State of Wyoming now owns 35,251 shares of the company’s stock valued at $221,000 after purchasing an additional 24,716 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in OptimizeRx by 131.7% in the first quarter. Principal Financial Group Inc. now owns 63,790 shares of the company’s stock valued at $401,000 after purchasing an additional 36,259 shares during the period. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.